Bio-Techne (TECH) announced the launch of an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with industry-leading sensitivity and specificity, the Advanced Cell Diagnostics branded RNAscope probe portfolio now includes over 70,000 unique probes across over 450 species.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Electronic Arts initiated, Workday downgraded: Wall Street’s top analyst calls
- Bio-Techne downgraded to Neutral from Outperform at Baird
- Bio-Techne’s Strong Growth Prospects and Strategic Positioning Drive Buy Rating
- Bio-Techne price target raised to $90 from $88 at Scotiabank
- Bio-Techne’s Strong Growth Prospects and Buy Rating Amidst Robust Q2 Results and Expanding Market Presence